Cannabis Law Report
JULY 6, 2021
Drug Enforcement Agency’s approach, the DEA has notified marijuana grower applicants that they soon will be able to register as authorized entities to produce marijuana for research purposes. Prior to this announcement, there was only one DEA-approved supplier of cannabis for research purposes in the entire country.
Cannabis Law Report
JULY 12, 2019
This differs sharply from the conventional course of cannabis medicine, which is to use whole, clean plant extracts to treat epilepsy and to gradually discontinue use of conventional pharmaceuticals. An Israeli study of cannabis versus epilepsy, however, used natural extracts with a ratio of 20:1 CBD:THC. References. 1Alexandra L.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Joint Blog
SEPTEMBER 19, 2019
Food and Drug Administration has approved one CBD-based medicine for treating seizures associated with two rare and severe forms of epilepsy but says it cannot be added to food, drinks or dietary supplements. The packaging doesn’t identify the companies and their brands have little online presence. and New Zealand.
CannaMD
SEPTEMBER 15, 2020
Patients suffering from cancer, epilepsy, chronic seizures, or muscle spasms could use low-THC cannabis products recommended by a licensed doctor. SHORT ANSWER: Yes, but products must be contained in their original packaging. Have permanent or temporary residency in the state of Florida. Crohn’s Disease. Multiple Sclerosis.
Cannabis Law Report
SEPTEMBER 23, 2019
The AAFP advocates for robust regulation regarding labeling and child-proof packaging of all marijuana and cannabinoid products. Due to the Schedule I classification by the Drug Enforcement Agency (DEA), researchers seeking to investigate health effects associated with cannabis must follow a regimented application process.
Expert insights. Personalized for you.
105 
Let's personalize your content